Company news
Biome Australia Ltd (ASX:BIO) news
Biome Australia Ltd news releases on 6ix. Latest, Jan 15, 2024: Biome to launch into UK and Ireland health retail
Press releases — page 2
Biome to launch into UK and Ireland health retail
January 14, 2024
FY24 Revenue Guidance Upgrade to $12.5M
January 7, 2024
Biome Achieves Record Quarter and Half Year Sales
January 1, 2024
Biome to launch cholesterol reducing probiotic
December 20, 2023
Biome signs landmark agreement to develop IP
December 10, 2023
Revenue Update
November 27, 2023
Biome expects first month of positive EBITDA in FY24
October 8, 2023
Biome Lift Clinical Trial Presentation
July 5, 2023
Biome Lift trial update positive results received
July 5, 2023
Full year revenue guidance FY23
July 3, 2023
Biome secures $1.2 million revolving debt facility
June 27, 2023
Biome surpasses $7m sales revenue target
June 14, 2023
Correction to Quarterly Activities Report
April 20, 2023
Biome delivers record quarterly sales in Q3 FY23
April 2, 2023
Biome signs corporate advisory mandate with Canary Capital
March 30, 2023
Biome H1 FY23 Investor Presentation
March 5, 2023
Biome records record H1 sales revenue
January 8, 2023
FY23 Q1 Sales Revenue Update and FY23 Forecast
October 3, 2022
FY22 Company Presentation
October 3, 2022
FY23 Trading Update
September 20, 2022
Biome Lift Clinical Trial Hits Recruitment Target
August 31, 2022
Delivery of Activated Probiotics to 370 Priceline Pharmacies
August 31, 2022
FY22 Revenue Guidance
July 3, 2022
Biome signs distribution agreement with Priceline Pharmacy
May 29, 2022
FY22 Trading Update
May 17, 2022
Record H1 sales deliver 98% revenue growth
February 27, 2022
Appendix 4D and Half Yearly Report
February 27, 2022
Ethics approval received for Biome Daily Kids clinical trial
February 23, 2022
Biome Clinical Development Update
February 20, 2022
Supplementary announcement Acne clinical trial
February 13, 2022
Successful acne clinical trial result with product to launch
February 8, 2022
Clinical trial on asthma sufferers validates Biome probiotic
February 1, 2022
Investor Update
December 2, 2021